Neurobiology of Aging
Volume 30, Issue 10 , Pages 1552-1562 , October 2009

Differential processing and secretion of Aβ peptides and sAPPα in human platelets is regulated by thrombin and prostaglandine 2

  • A. Smirnov

      Affiliations

    • Department of Psychiatry and Psychotherapy, University Hospital of Erlangen, Germany
    • ,
  • A. Trupp

      Affiliations

    • Department of Psychiatry, Georg-August University of Göttingen, Germany
    • ,
  • A.W. Henkel

      Affiliations

    • Department of Psychiatry and Psychotherapy, University Hospital of Erlangen, Germany
    • ,
  • E. Bloch

      Affiliations

    • Department of Psychiatry, Georg-August University of Göttingen, Germany
    • ,
  • U. Reulbach

      Affiliations

    • Department of Psychiatry and Psychotherapy, University Hospital of Erlangen, Germany
    • ,
  • P. Lewczuk

      Affiliations

    • Department of Psychiatry and Psychotherapy, University Hospital of Erlangen, Germany
    • ,
  • J. Riggert

      Affiliations

    • Department of Transfusion Medicine, Georg-August University of Göttingen, Germany
    • ,
  • J. Kornhuber

      Affiliations

    • Department of Psychiatry and Psychotherapy, University Hospital of Erlangen, Germany
    • ,
  • J. Wiltfang

      Affiliations

    • Department of Psychiatry and Psychotherapy, University Hospital of Erlangen, Germany
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry and Psychotherapy (Molecular Neurobiology), University Hospital of Erlangen, Schwabachanlage 6, 91054 Erlangen, Germany. Tel.: +49 9131 853 6896; fax: +49 9131 853 6381.

Received 2 February 2007 ,Revised 6 December 2007 ,Accepted 11 December 2007.

References 

  1. Abraham CR, Marshall DC, Tibbles HE, Otto K, Long HJ, Billingslea AM, et al. Platelets and DAMI megakaryocytes possess beta-secretase-like activity. J. Lab. Clin. Med. 1999;133(5):507–515
  2. Bateman DA, McLaurin J, Chakrabartty A. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. BMC Neurosci. 2007;8:29
  3. Bibl M, Esselmann H, Mollenhauer B, Wiltfang J. Aminoterminally truncated and oxidized amyloid-beta peptide species in Alzheimer's disease. Neuroscience. 2007;146(1):17–18
  4. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis. 2004;25(17):2912–2918
  5. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, et al. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J. Neural. Transm. 2006;113(11):1771–1778
  6. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry. 2007;
  7. Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull. 2003;61(3):235–242
  8. Borroni B, Colciaghi F, Corsini P, Akkawi N, Rozzini L, Del Zotto E, et al. Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms. Neurol. Sci. 2002;23(5):207–210
  9. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, et al The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. Biol. Chem. 1990;265(26):15977–15983
  10. Casoli T, Di Stefano G, Giorgetti B, Grossi Y, Balietti M, Fattoretti P, et al. Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann. N.Y. Acad. Sci. 2007;1096:170–178
  11. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun. 1995;213(1):96–103
  12. Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, et al. [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol. Med. 2002;8(2):67–74
  13. Da Prada M, Cesura AM, Launay JM, Richards JG. Platelets as a model for neurones?. Experientia. 1988;44(2):115–126
  14. Davies TA, Long HJ, Eisenhauer PB, Hastey R, Cribbs DH, Fine RE, et al. Beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. Amyloid. 2000;7(3):153–165
  15. DeMayer . Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease. Cariovasc. Hematol. Disord. Drug Targets. 2006;6:21–34
  16. Di Luca M, Colciaghi F, Pastorino L, Borroni B, Padovani A, Cattabeni F. Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. Eur. J. Pharmacol. 2000;405(1–3):277–283
  17. Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch. Neurol. 1998;55(9):1195–1200
  18. Eckert A, Cotman CW, Zerfass R, Hennerici M, Muller WE. Lymphocytes as cell model to study apoptosis in Alzheimer's disease: vulnerability to programmed cell death appears to be altered. J. Neural. Transm. Suppl. 1998;54:259–267
  19. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J. Neurosci. Res. 2003;74(3):386–392
  20. Giri R, Selvaraj S, Miller CA, Hofman F, Yan SD, Stern D, et al. Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium. Am. J. Physiol. Cell Physiol. 2002;283(3):C895–C904
  21. Gray SJ, Heptinstall S. The effects of PGE2 and CL 115, 347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility. Eur. J. Pharmacol. 1985;114(2):129–137
  22. Handagama P, Bainton DF, Jacques Y, Conn MT, Lazarus RA, Shuman MA. Kistrin, an integrin antagonist, blocks endocytosis of fibrinogen into guinea pig megakaryocyte and platelet alpha-granules. J. Clin. Invest. 1993;91(1):193–200
  23. Hartmann T. Intracellular biology of Alzheimer's disease amyloid beta peptide. Eur. Arch. Psychiatry Clin. Neurosci. 1999;249(6):291–298
  24. Hedin HL, Eriksson S, Fowler CJ. Human platelet calcium mobilisation in response to beta-amyloid (25–35): buffer dependency and unchanged response in Alzheimer's disease. Neurochem. Int. 2001;38(2):145–151
  25. Jans DM, Martinet W, Fillet M, Kockx MM, Merville MP, Bult H, et al. Effect of non-steroidal anti-inflammatory drugs on amyloid-beta formation and macrophage activation after platelet phagocytosis. J. Cardiovasc. Pharmacol. 2004;43(3):462–470
  26. Jolly-Tornetta C, Wolf BA. Regulation of amyloid precursor protein (APP) secretion by protein kinase calpha in human ntera 2 neurons (NT2N). Biochemistry. 2000;39(25):7428–7435
  27. Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H. Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. Nature. 1988;331(6156):530–532
  28. Kowalska MA, Badellino K. beta-Amyloid protein induces platelet aggregation and supports platelet adhesion. Biochem. Biophys. Res. Commun. 1994;205(3):1829–1835
  29. Lewczuk P, Esselmann H, Bibl M, Paul S, Svitek J, Miertschischk J, et al. Electrophoretic separation of amyloid beta peptides in plasma. Electrophoresis. 2004;25(20):3336–3343
  30. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol. Aging. 2007;
  31. Li Q-X, Cappai R, Evin G, Tanner JE, Gray CW, Beyreuther K, et al. Products of the Alzheimer's disease amyloid precursor protein generated by β-secretase are present in human platelets, and secreted upon degranulation. Am. J. Alzheimer's Dis. 1998;13:236–244
  32. Li Q, Berndt M, Bush AI, Rumble B, Mackenzie I, Friedhuber A, et al. Membrane associated forms of that βA4 amyloid protein precursor of Alzheimer's disease in human platelet and brain:surface expression on the activated human platelets. Blood. 1994;84(1):133–142
  33. Li QX, Fuller SJ, Beyreuther K, Masters CL. The amyloid precursor protein of Alzheimer disease in human brain and blood. J. Leukoc. Biol. 1999;66(4):567–574
  34. Mattson MP. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Ann. N.Y. Acad. Sci. 1994;747:50–76
  35. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, et al. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron. 1992;9(1):129–137
  36. Mönning U, König G, Prior R, Mechler H, Schreiter-Gasser U, Masters CL, et al. Synthesis and secretion of Alzheimer amyloid beta A4 precursor protein by stimulated human peripheral blood leucocytes. FEBS Lett. 1990;277(1–2):261–266
  37. Pluta R. Blood-brain barrier dysfunction and amyloid precursor protein accumulation in microvascular compartment following ischemia-reperfusion brain injury with 1-year survival. Acta Neurochir. Suppl. 2003;86:117–122
  38. Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets are Higher in Amnestic Versus Nonamnestic Patients With Mild Cognitive Impairment. Alzheimer Dis. Assoc. Disord. 2007;21(3):259–261
  39. Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GL. Coated-platelets retain amyloid precursor protein on their surface. Platelets. 2006;17(1):56–60
  40. Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, et al. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. 1998;18(5):1743–1752
  41. Schlossmacher MG, Ostaszewski BL, Hecker LI, Celi A, Haass C, Chin D, et al. Detection of distinct isoform patterns of the beta-amyloid precursor protein in human platelets and lymphocytes. Neurobiol. Aging. 1992;13(3):421–434
  42. Schmaier AH, Dahl LD, Hasan AA, Cines DB, Bauer KA, Van Nostrand WE. Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. Biochemistry. 1995;34(4):1171–1178
  43. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 2000;275(4):2568–2575
  44. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J. Neurol. Sci. 2006;240(1–2):53–58
  45. Van Nostrand WE, Schmaier AH, Farrow JS, Cines DB, Cunningham DD. Protease nexin-2/amyloid beta-protein precursor in blood is a platelet-specific protein. Biochem. Biophys. Res. Commun. 1991;175(1):15–21
  46. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 1989;57(1):115–126
  47. Weltzien RB, Pachter JS. Visualization of beta-amyloid peptide (Abeta) phagocytosis by human mononuclear phagocytes: dependency on Abeta aggregate size. J. Neurosci. Res. 2000;59(4):522–527
  48. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J. Neurochem. 2007;101(4):1053–1059
  49. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 2002;81(3):481–496
  50. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, et al. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann. Neurol. 2003;54(2):263–267
  51. Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P, et al. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry. 2005;6(2):69–84
  52. Wiltfang J, Smirnov A, Schnierstein B, Kelemen G, Matthies U, Klafki HW, et al. Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis. 1997;18(3–4):527–532
  53. Xu F, Previti ML, Van Nostrand WE. Increased severity of hemorrhage in transgenic mice expressing cerebral protease nexin-2/amyloid beta-protein precursor. Stroke. 2007;38(9):2598–2601
  54. Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol. Dis. 2005;19(1–2):237–242

PII: S0197-4580(07)00471-X

doi: 10.1016/j.neurobiolaging.2007.12.009

Neurobiology of Aging
Volume 30, Issue 10 , Pages 1552-1562 , October 2009

Article Tools

* Image Usage & Resolution